There are 10 products in the pipeline for microbial keratitis, an ocular infection...
Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)
Beovu® (brolucizumab) is an anti-vascular endothelial growth factor (anti-VEGF) drug indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Aerie’s netarsudil shows promise in Phase II trial in Japan
Aerie Pharmaceuticals has reported positive top-line results from the Phase II clinical trial of netarsudil ophthalmic solution conducted in open-angle glaucoma or ocular hypertension patients in Japan.
Aurinia starts voclosporin dosing in Phase II/III study
Aurinia Pharmaceuticals has started dosing patients in a Phase II/III clinical trial of voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
IVERIC bio reports positive results for Zimura in dry AMD trial
IVERIC bio has reported positive initial results from an ongoing Phase IIb clinical trial of Zimura (avacincaptad pegol) in patients suffering from dry age-related macular degeneration (AMD).
ONL Therapeutics trials ONL1204 to treat retinal detachment
Biopharmaceutical company ONL Therapeutics has commenced a Phase I clinical trial to assess its investigational drug, ONL1204, for the treatment of macula-off rhegmatogenous retinal detachment (RRD).
Focus shifts to gene therapy in the pipeline for treatment-resistant microbial keratitis
There are 10 products in the pipeline for microbial keratitis, an ocular infection of the cornea.
Two uveitis drugs show similarity in head-to-head study
An international, head-to-head clinical trial funded by the National Eye Institute has demonstrated similar performance by two uveitis drugs, methotrexate and mycophenolate mofetil.
Opthea reports positive data from Phase IIb trial in wet AMD
Australian biopharmaceutical firm Opthea has reported positive data from the Phase IIb clinical trial of OPT-302 in combination with ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration (AMD).
Oxurion reports mixed results from Phase IIa DME study
Oxurion has reported top-line results from the Phase IIa clinical trial of THR-317 in combination with ranibizumab to treat diabetic macular edema (DME) patients.
Outlook Therapeutics closes enrolment in Phase III wet AMD study
Outlook Therapeutics has concluded the enrolment of patients in a Phase III clinical trial of ONS-5010 for the treatment of patients with wet age-related macular degeneration (wet AMD).